RHYTHM BIOSCIENCES ORD
Rhythm Biosciences’ 2G ColoSTAT colorectal cancer detection kit outperforms predecessor in key testing
Medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed that the second version of its ColoSTAT kit for the detection of colorectal cancer has shown significant outperformance on the original. Preliminary testing of 200 patient serum samples using the new multiplex Alpha antibody kit has revealed superior analytical results compared to tests performed on the […]
Rhythm Biosciences receives UKCA mark for ColoSTAT colorectal blood test kit
A simple blood test used for the detection of colorectal cancer has achieved UK Conformity Assessed (UKCA) marking for developer Rhythm Biosciences (ASX: RHY). The regulatory milestone proves the ColoSTAT kit fully conforms with the European Directives for IVD Medical Devices (98/79/EC) and moves it a step closer to commercialisation in the UK. The achievement […]
Rhythm Biosciences reports positive results for lead biomarker in blood test for colorectal cancer screening
Australian medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed the antibodies in a lead biomarker of a blood test for the accurate and early detection of colorectal cancer have been successfully validated, stabilised and proven to be reproduceable. The biomarker can differentiate between cancerous and healthy blood samples and makes up the principal ingredient […]
Rhythm Biosciences advances development of novel colorectal cancer test
Medical diagnostics technology company Rhythm Biosciences (ASX: RHY) is continuing the development of its novel test for colorectal cancer, named ColoSTAT. As part of this work, the company says it has achieved a major technical achievement by isolating four cell lines that produce monoclonal antibodies. Rhythm said that its development of reagents is currently “ahead […]
